Research & Publications
For a complete list of publications, please visit PubMed.gov
Please click on the title to access PDF versions of our publications.
Weight loss in patients on osimertinib for metastatic EGFR-mutant non-small cell lung cancer
Chen LN, Ma X, Herzberg B, Henick BS, Biswas AK, Acharyya S, Shu CA. Weight loss in patients on osimertinib for metastatic EGFR-mutant non-small cell lung cancer. Oncologist. 2025 Aug 4;30(8):oyae315. doi: 10.1093/oncolo/oyae315. PMID: 39703162; PMCID: PMC12395254.
Garlin Politis M, Mansukhani M, Herzberg BO, Chen LN, Stoopler M, Saliba M, Siegelin M, Zhu Z, Sonett J, Henick BS, Cheng SK, Acharyya S, Shu CA, Miller ML, Izar B, Fernandes H, Hsiao S, Saqi A. Central Nervous System Metastases from Primary Lung Carcinoma: Significance of RNA Fusion Testing and Early Versus Late Metastases. J Pers Med. 2025 May 1;15(5):181. doi: 10.3390/jpm15050181. PMID: 40423053; PMCID: PMC12112828.
A new, immunocompetent brain-metastatic mouse model of HER2-positive breast cancer
Chen L, Chow A, Ma W, Coker C, Gu Y, Canoll P, Kandpal M, Hibshoosh H, Biswas AK, Acharyya S. A new, immunocompetent brain-metastatic mouse model of HER2-positive breast cancer. Clin Exp Metastasis. 2025 Apr 12;42(3):25. doi: 10.1007/s10585-025-10343-4. PMID: 40220135.
Weight loss in patients on osimertinib for metastatic EGFR-mutant non-small cell lung cancer
Chen LN, Ma X, Herzberg B, Henick BS, Biswas AK, Acharyya S, Shu CA. Weight loss in patients on osimertinib for metastatic EGFR-mutant non-small cell lung cancer. Oncologist. 2024 Dec 19:oyae315. doi: 10.1093/oncolo/oyae315. Epub ahead of print. PMID: 39703162.
FLT1 activation in cancer cells promotes PARP-inhibitor resistance in breast cancer
Tai Y, Chow A, Han S, Coker C, Ma W, Gu Y, Estrada Navarro V, Kandpal M, Hibshoosh H, Kalinsky K, Manova-Todorova K, Safonov A, Walsh EM, Robson M, Norton L, Baer R, Merghoub T, Biswas AK, Acharyya S. FLT1 activation in cancer cells promotes PARP-inhibitor resistance in breast cancer. EMBO Mol Med. 2024 Jul 2. doi: 10.1038/s44321-024-00094-2. Epub ahead of print. PMID: 38956205.
Biswas AK, Han S, Tai Y, Ma W, Coker C, Quinn SA, Shakri AR, Zhong TJ, Scholze H, Lagos GG, Mela A, Manova-Todorova K, de Stanchina E, Ferrando AA, Mendelsohn C, Canoll P, Yu HA, Paik PK, Saqi A, Shu CA, Kris MG, Massague J, Acharyya S. Cancer Discov. 2022 Jan 25:candisc.0910.2021.
PMID: 35078784. doi: 10.1158/2159-8290.CD-21-0910. Epub ahead of print.
Paik PK, Luo J, Ai N, Kim R, Ahn L, Biswas A, Coker C, Ma W, Wong P, Buonocore DJ, Lai WV, Chaft JE, Acharyya S, Massagué J, Kris MG. Phase I trial of the TNF-α inhibitor certolizumab plus chemotherapy in stage IV lung adenocarcinomas. Nat Commun. 2022 Oct 15;13(1):6095. doi: 10.1038/s41467-022-33719-6. PMID: 36241629; PMCID: PMC9568581.
Understanding cachexia in the context of metastatic progression.
Biswas AK, Acharyya S Nat Rev Cancer. 2020. PMID: 32235902, DOI: 10.1038/s41568-020-0251-4
Metastatic cancers promote cachexia through ZIP14 upregulation in skeletal muscle.
Wang G, Biswas AK, Ma W, Kandpal M, Coker C, Grandgenett PM, Hollingsworth MA, Jain R, Tanji K, Lόpez-Pintado S, Borczuk A, Hebert D, Jenkitkasemwong S, Hojyo S, Davuluri RV, Knutson MD, Fukada T, Acharyya S Nat Med. 2018. PMID: 29875463, DOI: 10.1038/s41591-018-0054-2
A CXCL1 paracrine network links cancer chemoresistance and metastasis.
Acharyya S, Oskarsson T, Vanharanta S, Malladi S, Kim J, Morris PG, Manova-Todorova K, Leversha M, Hogg N, Seshan VE, Norton L, Brogi E, Massagué J Cell. 2012. PMID: 22770218, DOI: 10.1016/j.cell.2012.04.042
Breast cancer cells produce tenascin C as a metastatic niche component to colonize the lungs.
Oskarsson T, Acharyya S, Zhang XH, Vanharanta S, Tavazoie SF, Morris PG, Downey RJ, Manova-Todorova K, Brogi E, Massagué J Nat Med. 2011. PMID: 21706029, DOI: 10.1038/nm.2379
Acharyya S, Villalta SA, Bakkar N, Bupha-Intr T, Janssen PM, Carathers M, Li ZW, Beg AA, Ghosh S, Sahenk Z, Weinstein M, Gardner KL, Rafael-Fortney JA, Karin M, Tidball JG, Baldwin AS, Guttridge DC J Clin Invest. 2007. PMID: 17380205, DOI: 10.1172/JCI30556
Acharyya S, Butchbach ME, Sahenk Z, Wang H, Saji M, Carathers M, Ringel MD, Skipworth RJ, Fearon KC, Hollingsworth MA, Muscarella P, Burghes AH, Rafael-Fortney JA, Guttridge DC Cancer Cell. 2005. PMID: 16286249, DOI: 10.1016/j.ccr.2005.10.004
Cancer cachexia is regulated by selective targeting of skeletal muscle gene products.
Acharyya S, Ladner KJ, Nelsen LL, Damrauer J, Reiser PJ, Swoap S, Guttridge DC
J Clin Invest. 2004. PMID: 15286803, DOI: 10.1172/JCI20174